Pharmacologic SubstanceAmino Acid, Peptide, or Protein
nci:P108
Buserelin
nci:P175
725176
nci:P207
C0006456
nci:P210
57982-77-1
nci:P302
Breast cancer; Contraception, female; Endometriosis; Infertility; in vitro fertilization; Polycystic ovary syndrome; Prostate cancer; Uterine leiomyoma
nci:P303
Prostate cancer
nci:P319
PXW8U3YXDV
nci:P322
FDA
nci:P325
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>An anticancer drug that belongs to the family of drugs called gonadotropin-releasing hormones. In prostate cancer therapy, buserelin blocks the production of testosterone in the testicles.</n0:def-definition><n0:def-source>NCI-GLOSS</n0:def-source></n0:ComplexDefinition>
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A synthetic analog of gonadotropin-releasing hormone (GnRH). Buserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of buserelin results in sustained inhibition of gonadotropin production, suppression of testicular and ovarian steroidogenesis, and reduced levels of circulating gonadotropin and gonadal steroids. Buserelin is more potent that GnRH. (NCI04)</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>